Rethinking bone marrow biopsy: is PET/CT enough for staging low-grade follicular lymphomas?
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06487-8 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Yan-Yan Chen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy f…. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Positron Emission Tomography Computed Tomography, Bone Marrow. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province, China.
Abstract (Originalsprache)
This study evaluates the diagnostic performance of staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for detecting bone marrow involvement (BMI) in low-grade follicular lymphoma (FL) and its impact on the clinical necessity of bone marrow biopsy (BMB). We retrospectively analyzed patients newly diagnosed with low-grade (grade 1-2) FL who underwent both 18F-FDG PET/CT and BMB from 2010 to 2022 at two Chinese institutions. PET/CT's diagnostic accuracy for BMI was assessed using BMB as gold standard. Clinical and imaging data were analyzed to identify risk factors for BMI. Among 171 patients, 27 had positive BMB results. PET/CT demonstrated 86.5% accuracy in detecting BMI. In patients with PET/CT-based stage I-II disease, all BMB results were negative. In contrast, among patients with PET/CT-based stage III-IV disease, BMB upstaged 13 to stage IV. In patients with advanced-stage disease as determined by PET/CT, four risk factors were significantly linked to BMB positivity: female sex, Eastern Cooperative Oncology Group performance score > 1, elevated beta2-microglobulin levels, and involvement of > 4 lymph node regions. Patients were stratified into low-, intermediate-, and high-risk groups with corresponding BMB-positive rates of 5.6%, 40.7%, and 68.8%, respectively. No survival differences were observed between BMB-positive and BMB-negative patients. PET/CT can safely and effectively substitute for BMB in the staging of early-stage, low-grade FL. However, in advanced-stage disease, BMB remains valuable for diagnosis. The rate of BMB positivity correlates with tumor burden -related risk factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors (Fujian Medical University), Clinical Research Center for Ra…
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, P. R. China.
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510030, P. R. China.
- Department of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fuzhou, P. R. China.
- Department of PET/CT, Fujian Medical University Union Hospital, Fuzhou, P. R. China.
- Follow-Up Center, Fujian Medical University Union Hospital, Fuzhou, P. R. China.
Förderung
- Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province, China
Zitieren
APA
Chen, Y. Y., Wang, J. J., Zhong, W. H., Guo, J. R., Qiu, Y. Y., Liu, T. X., Zheng, H., Chen, S. L., Liao, S. Q., Zhao, R. Z., Shi, G. Q., Tang, T. L., Lin, Y. P., Huang, C., Chen, J. H., Liu, T. B., Zhang, Y. J., & Yang, Y. (2025). Rethinking bone marrow biopsy: is PET/CT enough for staging low-grade follicular lymphomas?. Annals of Hematology. https://doi.org/10.1007/s00277-025-06487-8
Vancouver
Chen YY, Wang JJ, Zhong WH, Guo JR, Qiu YY, Liu TX, et al. Rethinking bone marrow biopsy: is PET/CT enough for staging low-grade follicular lymphomas?. Annals of Hematology. 2025. doi:10.1007/s00277-025-06487-8
BibTeX
@article{Chen2025,
author = {Chen, Yan-Yan and Wang, Ji-Jin and Zhong, Wen-Huan and Guo, Jiang-Rui and Qiu, Yan-Yan and Liu, Tian-Xiu and Zheng, Hao and Chen, Si-Lin and Liao, Si-Qin and Zhao, Rui-Zhi and Shi, Gui-Qing and Tang, Tian-Lan and Lin, Yu-Ping and Huang, Cheng and Chen, Jin-Hua and Liu, Ting-Bo and Zhang, Yu-Jing and Yang, Yong},
title = {Rethinking bone marrow biopsy: is PET/CT enough for staging low-grade follicular lymphomas?},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06487-8}
}
EUVIMED